I like this statement from the report - " that the molecularly targeted nanoparticles exhibit a unique and
observable molecular imaging ‘signature’ when cancer cells are present."
and that an expert panel will report on the results early Feb.
If these results are positive then that will go well for the option call on IBXOA that expires April. Perhaps the cash raised from the call will mean a capital raise can be postponed to a later date.
This is all my opinion and not advice.
I like this statement from the report - " that the molecularly...
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
